Y Intercept Hong Kong Ltd Purchases Shares of 13,722 Celcuity Inc. (NASDAQ:CELC)

Y Intercept Hong Kong Ltd acquired a new position in shares of Celcuity Inc. (NASDAQ:CELC) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 13,722 shares of the company’s stock, valued at approximately $205,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CELC. nVerses Capital LLC acquired a new stake in Celcuity during the 3rd quarter valued at approximately $33,000. Prospera Private Wealth LLC bought a new position in Celcuity during the third quarter worth $35,000. Values First Advisors Inc. bought a new position in Celcuity during the third quarter worth $86,000. Quest Partners LLC lifted its holdings in Celcuity by 31.3% in the second quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock valued at $95,000 after buying an additional 1,379 shares during the period. Finally, SG Americas Securities LLC bought a new stake in Celcuity during the third quarter valued at $119,000. 63.33% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CELC has been the topic of a number of recent analyst reports. Stifel Nicolaus boosted their price objective on Celcuity from $39.00 to $42.00 and gave the company a “buy” rating in a research note on Monday, October 7th. Lifesci Capital initiated coverage on Celcuity in a research note on Monday, August 26th. They issued an “outperform” rating and a $27.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price objective on shares of Celcuity in a research report on Friday, November 15th. Finally, Needham & Company LLC reissued a “buy” rating and set a $23.00 target price on shares of Celcuity in a research note on Friday, November 15th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $29.17.

Celcuity Price Performance

Shares of CELC opened at $12.00 on Friday. The business’s fifty day moving average is $14.14 and its 200 day moving average is $15.40. Celcuity Inc. has a 12-month low of $11.51 and a 12-month high of $22.19. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65. The stock has a market cap of $445.56 million, a P/E ratio of -4.60 and a beta of 0.74.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.